CareTrust REIT vs Sabra Health Care REIT
CTRE and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTRE and SBRA compare
CareTrust REIT is the larger company, worth 1.7 times as much as Sabra Health Care REIT ($8.6B against $5.0B).
On earnings, CareTrust REIT is cheaper: it trades at 22.9× trailing earnings, against 75.9× for Sabra Health Care REIT.
CareTrust REIT grew revenue faster over the last twelve months (53.0% versus 17.3% for Sabra Health Care REIT).
CareTrust REIT keeps more of each dollar of sales as profit, with a net margin of 62.2% compared with 7.6% at Sabra Health Care REIT.
Both pay dividends: CareTrust REIT yields 4.1% and Sabra Health Care REIT 6.1%.
CareTrust REIT scores higher on the StockData Score (15 against 7 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTRE | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $8.6B | $5.0B |
| Share price | $36.39 | $19.74 |
| Change, 1 year | 7.1% | 14.6% |
| Change, 5 years | 72.5% | 32.2% |
| Beta (5Y) | 0.52 | 0.48 |
| Employees | 43 | 58 |
| StockData Score | ||
| Total score | 15 (better) | 7 |
| Valuation score | 2 (better) | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 1 (better) | 0 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 22.9× (better) | 75.9× |
| P/S | 15.0× | 5.9× (better) |
| P/B | 1.9× | 1.8× (better) |
| EV/EBITDA | 16.2× | 12.5× (better) |
| Fair value | $32.95 | $12.68 |
| Margin of safety | −10.4% (better) | −55.7% |
| Growth | ||
| Revenue growth (TTM) | 53.0% (better) | 17.3% |
| Revenue growth, 5Y average | 21.7% (better) | 5.3% |
| Net income growth (TTM) | 61.6% (better) | −64.1% |
| EPS growth (TTM) | 32.5% (better) | −65.8% |
| EPS growth, 5Y average | 13.1% (better) | −0.91% |
| Profitability | ||
| Net margin | 62.2% (better) | 7.6% |
| Return on equity | 9.1% (better) | 2.4% |
| Financial health | ||
| Altman Z-score | 3.74 (better) | 1.25 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 4.1% | 6.1% (better) |
| Payout ratio | 85.9% | 455% |
| Years of dividend growth | 11 (better) | 0 |
| Dividend growth, 5Y average | 6.0% (better) | −2.3% |
| Buyback yield | −13.8% | – |
| Shareholder yield | −9.7% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 106% | 102% |
| Held by insiders | 0.99% | 1.9% |
| Insider net buying, 12 months | – | −$4.5M |
| Short interest, % of float | 4.7% | 7.9% |
Go deeper
- CTRE stock overview
- CTRE income statement
- CTRE valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.